GlobeNewswire (Thu, 7:05AM)
Quote & Headlines
Market Currents
StockTalk
Description
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
4,826 people get GALE articles and Market Currents by email alert.
Get email alerts on GALE »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
GlobeNewswire (May 9, 2013)
-
GlobeNewswire (May 9, 2013)
-
-
GlobeNewswire (May 1, 2013)
-
GlobeNewswire (Apr 24, 2013)
-
-
GlobeNewswire (Apr 16, 2013)
-
-
-
-
GlobeNewswire (Mar 29, 2013)
-
-
-
-
To learn more about Seeking Alpha Pro, click here.
There are no Transcripts on GALE.
-
GlobeNewswire (Thu, 7:05AM)
-
GlobeNewswire (May 9, 2013)
-
GlobeNewswire (May 9, 2013)
-
GlobeNewswire (May 1, 2013)
-
GlobeNewswire (Apr 24, 2013)
-
GlobeNewswire (Apr 16, 2013)
-
GlobeNewswire (Mar 29, 2013)
-
GlobeNewswire (Mar 14, 2013)
-
GlobeNewswire (Mar 12, 2013)
-
GlobeNewswire (Mar 11, 2013)
-
GlobeNewswire (Mar 4, 2013)
-
GlobeNewswire (Feb 5, 2013)
-
GlobeNewswire (Dec 18, 2012)
-
GlobeNewswire (Dec 17, 2012)
-
GlobeNewswire (Dec 5, 2012)
-
GlobeNewswire (Dec 4, 2012)
GALE vs. ETF Alternatives
Company Description
Galena Biopharma, Inc. (Nasdaq:GALE) is a Portland, Oregon-based biopharmaceutical company that develops innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. For more information please visit us at www.galenabiopharma.com. More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
-
Wednesday, May 22, 9:17 AM
Premarket gainers: ZLC +30%. MBND +24%. CLNT +23%. SKS +18%. ONCY +10%. BIOF +9%. TOL +6%. NTAP +6%. YGE +5%. GALE +5%.
Losers: STP -9%. NBG -7%. BALT -9%. UAN -6%. Comment! [On the Move] - Thursday, May 9, 5:39 PM Galena Biopharma (GALE): Q1 EPS of -$0.11 misses by $0.04. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Monday, March 25, 11:31 AM Needham starts Galena Biopharma (GALE +4.1%) at Buy with $3.50 price target. When administered as an adjuvant, the investment bank says the company's breast cancer vaccine NeuVax shows promise. The vaccine is "one of the leading new product candidates" for adjuvant vaccine therapy which analyst Chad Messer says will "become the standard of care for many cancer types." The company recently acquired Abstral, a sublingual tablet indicated for cancer pain which notched $54M in sales in Europe last year, for sale and distribution in the U.S. Comment! [Healthcare]
- Monday, March 18, 11:06 AM Galena Biopharma (GALE +3.4%) gains after saying its entered into an agreement with Swedish drug maker Orexo AB to acquire Abstral Sublingual Tablets for sale and distribution in the United States. Abstral was approved by the FDA in January 2011, and had $54M in sales in Europe in 2012. Under the terms of the agreement, GALE will pay Orexo $10M upfront and $5M within the first twelve months of closing, plus low double digit royalties and one-time milestone payments based on pre-specified net sales. Comment! [Healthcare, On the Move]
-
Monday, March 18, 9:10 AM
Premarket gainers: FU +19%. PRWT +9%. GALE +7%. CLSN +7%.
Losers: AMBO -15%. INCY -12%. FBN -11%. JVA -8%. NBG -6%. ING -6%. NVO -5%. Comment! [On the Move] -
Wednesday, February 20, 9:10 AM
Premarket gainers: NTSP +30%. NVGN +14%. JASO +9%. SINA +8%. GDOT +8%. THLD +8%. RMBS +8%. OMX +7%. ODP +7%. MDRX +6%. GALE +5%.
Losers: HNR -41%. MM -27%. ONCY -12%. GRMN -9%. LIFE -5%. Comment! [On the Move] -
Monday, February 4, 9:10 AM
Premarket gainers: APKT +23%. RMTI +22%. SONS +10%. PPHM +8%. CCUR +6%. GALE +6%.
Losers: HLF -9%. Comment! [On the Move] -
Tuesday, December 18, 2012, 12:45 PM
Midday top 10 gainers: BOSC +83%. OPXA +31%. MEIP +30%. ARB +24%. RNIN +21%. VNDA +21%. III +18%. NVGN +16%. SNFCA +14%. GDP +14%.
Midday top 10 Losers: AWRE -23%. CNH -18%. LEI -17%. GALE -17%. LIVE -16%. CIS -14%. GTAT -13%. MNGA -12%. RCMT -12%. SWHC -10%. Comment! [On the Move] - Tuesday, December 18, 2012, 10:35 AM Galena Biopharma (GALE -18.7%) discloses the details of its unspecified secondary offering announced late yesterday, saying it sold 15.2M units for gross proceeds of about $24.3M. The units - consisting of one share of stock and a warrant - priced at $1.60 each. The warrants entitle holders to purchase half a share at an exercise price of $1.90. The company intends to use the proceeds for clinical trials of its breast cancer treatment NeuVax and a trial of its Folate Binding Protein-E39. The company has a current float of around 67.6M shares. Comment! [Healthcare, On the Move]
-
Tuesday, December 18, 2012, 9:10 AM
Premarket gainers: VNDA +26%. ARB +24%. NOK +5%.
Losers: AWRE -24%. GALE -20%. GTAT -14%. RAS -6%. Comment! [On the Move] - Monday, December 17, 2012, 4:45 PM Galena Biopharma (GALE) slips 14% in the post-session after saying it intends to offer common stock and warrants for an unspecified amount. The company intends to use the net proceeds to conduct ongoing clinical trials for NeuVax and its Folate Binding Protein-E39. Piper Jaffray is acting as the sole book-running manager for the offering. 1 Comment [Healthcare, On the Move]
- Friday, December 7, 2012, 9:30 AM Galena Biopharma (GALE) +7.8% premarket after saying studies of its NeuVax treatment continue to demonstrate excellent safety and efficacy profiles. Comment! [Healthcare, On the Move]
-
Friday, December 7, 2012, 9:10 AM
Premarket gainers: GALE +9%. ACRX +7%.
Losers: AMRN -19%. ABMD -7%. QRE -5%. Comment! [On the Move] - Thursday, December 6, 2012, 8:48 AM Galena Biopharma (GALE) forms a partnership with Germany's Leica Biosystems to use the latter's Bond Oracle HER2 IHC System to help select patients for the Phase III trials of Galena's NeuVax breast cancer treatment. On Tuesday, Galena signed a deal with Teva for the commercialization of NeuVax in Israel. (PR) Comment! [Healthcare]
-
Tuesday, December 4, 2012, 9:10 AM
Premarket gainers: SINO +28%. GALE +14%. FHCO +10%. BIG +7%. OCZ +6%. ALXA +5%.
Losers: GERN -28%. PBY -9%. DRI -9%. SSN -6.4%. PCS -6.4%. Comment! [On the Move] - Tuesday, December 4, 2012, 8:24 AM Galena (GALE) soars 17.2% after signing a deal with Teva (TEVA) for the commercialization of its NeuVax breast cancer treatment in Israel. While financial terms weren't disclosed, Teva will make significant royalty payments to Galena on future sales. Israel will be the location of at least four sites for Phase 3 trials of NeuVax. Comment! [On the Move, Healthcare]
-
- View all 2 replies
-
JMattius: Ran too far too fast is my guess. See CPRX get shorted like crazy after it doubled in three days. -
-
- View all 0 replies
-
- View all 1 replies
-
Owen Bernard: Not sure you found any answers - most interesting was a new B.O.D. joined $GALE, William L. Ashton. Definitely an attention getter.
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 2 replies
-
-
-
- View all 0 replies
-
- View all 0 replies
-
Robert Schwartz
Galena Biopharma ($GALE): What to know before you invest http://seekingalpha.com/p/z54r - View all 3 replies
-
Robert Schwartz: They are missing quite a bit. Take a look at their characterization of the Phase-I/II-data, it is way off base.
-
isafin: So, the recent wobble of the stock price can be substantiated by other than speculative trends reasons. Thank you.
LATEST REPLIES
-
- View all 2 replies
-
JMattius: Ran too far too fast is my guess. See CPRX get shorted like crazy after it doubled in three days.
-
-
- View all 1 replies
-
Owen Bernard: Not sure you found any answers - most interesting was a new B.O.D. joined $GALE, William L. Ashton. Definitely an attention getter.
-
- View all 2 replies
-
-
-
Robert Schwartz
Galena Biopharma ($GALE): What to know before you invest http://seekingalpha.com/p/z54r - View all 3 replies
-
Robert Schwartz: They are missing quite a bit. Take a look at their characterization of the Phase-I/II-data, it is way off base.
-
isafin: So, the recent wobble of the stock price can be substantiated by other than speculative trends reasons. Thank you.
-
- View all 1 replies
-
Robbster: Tthese represent my "Dev. Biotech Fundamentals" strategy; breakthrough science, financials and leadership that support price appreciation.
-
Rich Steffens
If I had free $, I'd start my position in $GALE, especially after learning from COL GEP of AF's inaccuracies. - View all 12 replies
-
Ron Reed: week later when it falls back down. Great idea company just no sense in how to turn it into money for the investor.
-
Rich Steffens: 11/27 AF made false claims. GALE closed @ 1.58. A trade long was born. 11/29 @ 2.04. 12/04 @ 2.24. Take profit, when so high, add later.
-
- View all 1 replies
-
smokeyRose: Because it's A Bio-Pharm. They Have No Stability at all.........Unless of course someBody on the inside Knows about Drug approval and or Dis
-
- View all 2 replies
-
-
-
- View all 1 replies
-
-
- View all 2 replies
-
EvrClrx311: I'm sure in another year I'll be saying "wish I had owned more than just 5000 shares when GALE was at $2"
-
NYorkerinUT: You just never know sometimes. I was considering GALE when it was under a buck, but thought it might get de-listed or reverse split.
-
- View all 5 replies
-
-
-
- View all 4 replies
-
-
-
- View all 2 replies
-
-
-
- View all 1 replies
-
